Conference Coverage

Conference Coverage Videos

Complete Conference Coverage

New Drug Combinations Show Promise for Patients With Relapsed/Refractory Neuroblastoma

New Drug Combinations Show Promise for Patients With Relapsed/Refractory Neuroblastoma

Two novel regimens showed significant anti-tumor activity in patients with neuroblastoma.

Analysis Reveals Potentially Targetable Fusion Genes in Various Cancer Types

Analysis Reveals Potentially Targetable Fusion Genes in Various Cancer Types

An RNA assay for common gene fusions is now validated and available to guide patients with cancer to clinical trials and through drug treatment options.

Clinical Benefit for Patients When Treated Based on ctDNA Findings

Clinical Benefit for Patients When Treated Based on ctDNA Findings

Nearly half of patients with advanced cancer treated with FDA-approved therapies had alterations in circulating tumor DNA (ctDNA).

Serum Carbonic Anhydrase IV Predictive of Bevacizumab Efficacy in Breast Cancer

Serum Carbonic Anhydrase IV Predictive of Bevacizumab Efficacy in Breast Cancer

Serum levels of carbonic anhydrase IV (sCAIX) were associated with improved pathologic complete response rates.

Single-cell RNA-sequencing Can Resolve Malignant, Non-malignant Heterogeneity

Single-cell RNA-sequencing Can Resolve Malignant, Non-malignant Heterogeneity

Single-cell RNA-sequencing can resolve the heterogeneity of both malignant and non-malignant tumor components.

Funding, Informatics System, Clinical Data Capture Among Barriers to Effective Data Sharing

Funding, Informatics System, Clinical Data Capture Among Barriers to Effective Data Sharing

Funding, informatics system, clinical data capture, and European data protection legislation were considered the greatest barriers to effective data sharing.

Researchers Discuss Evolution of Immunotherapy Approaches for Gynecologic Malignancies

Researchers Discuss Evolution of Immunotherapy Approaches for Gynecologic Malignancies

Immunotherapy approaches are evolving for all types of gynecologic malignancies, including ovarian, cervical, and endometrial cancers.

Biosimilar to Trastuzumab Comparable in Efficacy, Safety for Advanced HER2+ Breast Cancer

Biosimilar to Trastuzumab Comparable in Efficacy, Safety for Advanced HER2+ Breast Cancer

MYL-1401O is comparable in efficacy and safety to the anti-HER2 monoclonal antibody trastuzumab as frontline therapy in breast cancer.

Substituting Nab-paclitaxel in Anthracycline Regimen Did Not Significantly Improve pCR in HER2-negative Breast Cancer

Substituting Nab-paclitaxel in Anthracycline Regimen Did Not Significantly Improve pCR in HER2-negative Breast Cancer

Replacing paclitaxel with nab-paclitaxel in an anthracycline regimen failed to significantly improve the pathologic complete response rate.

Study Evaluates Adding, Substituting Neoadjuvant Lapatinib for HER2+ Breast Cancer

Study Evaluates Adding, Substituting Neoadjuvant Lapatinib for HER2+ Breast Cancer

Adding lapatinib to trastuzumab plus weekly paclitaxel after an anthracycline was not beneficial.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs